In vitro inhibition of the paraoxonase from human serum with sulfonamide

African Journal of Biotechnology

Volumn 7, Issue 5, 2008, Pages 508-512

  Sinan, Selma ^a  

^a BALIKESIR UNIVERSITY   (Turkey)

Author keywords

in vitro; Inhibition; Paraoxonase; Sulfonamide

Indexed keywords

AMMONIUM SULFATE; ARYLDIALKYLPHOSPHATASE 1; NAPHTHYL GROUP; PARAOXON; PHENYLACETIC ACID; SEPHAROSE; SULFONAMIDE;

ARTICLE; CHROMATOGRAPHY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; IC 50; IN VITRO STUDY; PRECIPITATION;

EID: 40949165285     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik DS (2004). Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization, Proc. Natl. Acad. Sci. U.S.A., 101: 482-487.
2. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parma SL, La Du BN (1998). Paraoxonase inhibits highdensity lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest, 101: 1581-590.
3. Biggadike K, Angell RM, Burgess CM, Farrell RM, Hancock AP, Harker AJ, Irving WR, Ioannou C, Procopiou, PA, Shaw RE, Solanke YE, Singh OM Snowden M A, Stubbs R J, Walton S, Weston HE (2000). Selective plasma hydrolysis of glucocorticoid gammalactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism, J. Med. Chem 43: 19-21.
4. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN (2000). Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28: 1335-1342.
5. Boyd AE (1988). Sulfonylurea receptors, ion channels and fruit flies. Diabetes; 37: 847-850.
6. Bradford MM (1976). A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72: 248-251.
7. Costa LG, Cole TB, Jarvik GP, Furlong EF (2003). Functional Genomics of the Paraoxonase (PON1) Polymorphisms: Effects on Pesticide Sensitivty, Cardiovascular Disease, and Drug Metabolism, Annu. Rev. Med, 54: 371.
8. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE (1996). The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet 14: 334-336.
9. Drew J (2000) Drug discovery: A historical perspective. Science 287: 1960-1964.
10. Durrington PN, Mackness B, Mackness MJ (2001) Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 473-480
11. Eckerson HW, Romson J, Wyte C, La Du BN (1983). The human serum paraoxonase polymorphism:dentification of phenotypes by their response to salts. Am. J. Hum. Genet. 35:214-227.
12. Eiberg H, Mohr J (1986). Identity of the polymorphisms for esterase D and Sformylglutathione hydrolase in red blood cells. Hum Genet, 74: 174-175.
13. Gan KN, Smolen A, Eckerson HW, La Du BN (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities, Drug Metab. Dispos. 19: 100-106.
14. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS (2004). Corrigendum: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes, Nat. Struct. Mol. Biol. 11: 1253.
15. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE (1991). Characterisation of cDNA clones encoding rabbit andhuman serum paraoxonase: the mature protein retains itssignal sequence. Biochemistry, 30: 10141-10149.
16. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T (1995). Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab. Dispos. 23: 1022-1027.
17. Jakubowski H (2000). Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein n-homocysteinylation. J. Biol. Chem., 275: 3957-3962.
18. Khersonsky O, Tawfik DS (2005). Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase, Biochemistry 44: 6371-6382.
19. Khersonsky O, Tawfik DS (2006). The Histidine 115-Histidine 134 Dyad Mediates the Lactonase Activity of Mammalian Serum Paraoxonase. J. Biol. Chem. 281(11): 7649-7656.
20. Krasny HC, Beauchamp L, Krenitsky TA, Miranda PD (1995). Metabolism and pharmacokinetics of a double prodrug of ganciclovir in the rat and monkey. Drug Metab. Dispos. 23: 1242-247.
21. Lusis AJ (2000). Atherosclerosis. Nature 407: 233-241.
22. Mackness MI, Arrol S, Abbott C, Durrington PN (1993). Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 104: 129-135.
23. Maren TH (1976). Relations between structure and biological activity of sulfonamides. Annu. Rev. Pharmacol. Toxicol. 16:.309-327.
24. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AFL, Lockridge O, La Du BN (1989). Identification of the structural mutation responsible for the dibucaineresistant (atypical) variant form of human serum cholinesterase. Proc. Natl. Acad. Sci. USA, 86: 953-957.
25. Obermeier MT, Chong S, Dando SA, Marino AM, Ryono DE, Starret-Arroyo A, Didonato GC, Warrack BM, White RE, Morrison RA (1996). Prodrugs of BMS-183920. J. Pharm. Sci. 85: 828-833.
26. Ogden RC, Flexner CW, editors (2001). Protease Inhibitors in AIDS Therapy. New York, Basel: Marcel Dekker.
27. Playfer JR, Eze CL, Bullen MF, Evans DAP (1976). Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J. Med. Genet. 13: 337-342.
28. Primo-Parmo SL Sorenson RC, Teiber J, La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 33: 498-507.
29. Satoh T (1987). Role of carboxylesterases in xenobiotic metabolism. Rev Biochem Toxicol, 8: 155-181.
30. Senter PD, Marquardt H, Thomas BA, Hammock BD, Frank IS, Svensson HP (1996). The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res, 56: 1471-1474.
31. Scozzafava A, Supuran CT (2000). Carbonic anhydrase and matrix metalloproteinase inhibitors. Sulfonylated amino acid hydroxamates withMMP inhibitory properties act as efficient inhibitors of carbonic anhydrase isozymes I, II and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J. Med. Chem. 43: 3677-3687.
32. Sinan S, Kockar F, Arslan O (2006). Novel Purification Strategy For Human PON1 And Inhibition Of The Activity By Cephalosporin And Aminoglikozide Derived Antibiotics, Biochimie., 88: 565-574.
33. Supuran CT, Scozzafava A, Clare BW (2002). Bacterial protease inhibitors. Med. Res. Rev. 22:329-372.
34. Supuran CT. (2002). Indisulam. IDrugs, 5 :1075-1079. Supuran CT, Scozzafava A, Casini A (2003). Carbonic anhydrase inhibitors. Med. Res. Rev., 23: 146-189.
35. Supuran CT, Scozzafava A (2002). Applications of carbonic anhydrase inhibitors and activators in therapy. Exp. Opin. Ther. Patents; 12: 217-242.
36. Supuran CT, Scozzafava A (2001). Carbonic anhydrase inhibitors. Curr Med Chem- Imm Endoc Metab Agents 1: 61-97.
37. Supuran CT, ConroyCW, Maren TH (1996). Carbonic anhydrase inhibitors. Synthesis and inhibitory properties of 1,3,4-thiadiazole-2,5-bissulfonamide. Eur. J. Med. Chem. 31: 843-846.
38. Supuran CT, Casini A, Scozzafava (2003). Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents, Medicine research rewievs, 23(5): 535-558.
39. Tang BK, Kalow W (1995). Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. Eur. J. Clin. Pharmacol., 47: 449-451.
40. Thornber CW (1979). Isosterism and molecular modification in drug design. Chem. Soc. Rev., 8: 563-580.
41. Verpoorte JA, Mehta S, Edsall JT (1967). Esterase activities of human carbonic anhydrase B and C. J. Biol. Chem, 242: 4221-4229.
42. Williams FM (1985). Clinical significance of esterases in man. Clin. Pharmacokinet, 10: 392-403.